Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
|ClinicalTrials.gov Identifier: NCT02345824|
Recruitment Status : Unknown
Verified June 2018 by Camilo E. Fadul, MD, University of Virginia.
Recruitment status was: Active, not recruiting
First Posted : January 26, 2015
Last Update Posted : June 7, 2018
University of Virginia
Information provided by (Responsible Party):
Camilo E. Fadul, MD, University of Virginia
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||January 2020|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.